Physician profile
Christopher P Werner
NPI 1982836276
$4,771.98
in general payments reported to CMS, 2019-2025
25 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $555 · 2021: $1,708 · 2022: $300 · 2023: $273 · 2024: $826 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232 · Travel and Lodging: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.88 |
| Travel and Lodging | $309.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,933.75 | 2019-2024 | Gamma, T2, Augment Injectable |
| Pylant Medical | $1,321.84 | 2021-2024 | |
| Arthrex, INC. | $309.60 | 2024 | |
| Abbott Laboratories | $173.82 | 2024-2025 | Esprit, Proclaim |
| Orthofix Medical, INC. | $155.97 | 2019-2020 | |
| Kerecis Limited | $147.36 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Smith+Nephew, INC. | $118.64 | 2019-2021 | |
| Arthrosurface Incorporated | $101.99 | 2020 | |
| Averitas Pharma INC. | $73.08 | 2024 | Qutenza |
| Anika Therapeutics, INC. | $57.15 | 2025 | Tactoset |
| Wright Medical Technology, INC. | $46.44 | 2020 | |
| Amgen INC. | $35.56 | 2024-2025 | Krystexxa, Evenity, Prolia |
| Aroa Biosurgery Incorporated | $34.81 | 2024 | |
| Radius Health, INC. | $33.86 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $33.29 | 2020-2025 | Exparel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $30.79 | 2024 | |
| Depuy Synthes Sales INC. | $27.59 | 2019 | |
| Ferring Pharmaceuticals INC. | $25.43 | 2025 | Euflexxa |
| Innovation Technologies INC | $24.78 | 2024 | Irrisept |
| Davol INC. | $20.12 | 2025 | Surgiphor |
| Polynovo North America LLC | $17.51 | 2025 | Novosorb Btm |
| Organogenesis INC. | $13.68 | 2022 | |
| Acell, INC. | $12.89 | 2020 | |
| Cashflow Solutions, LLC | $11.20 | 2024 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Arteriocyte Medical Systems, INC. | $10.83 | 2024 | Magellan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.